Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuxiMAb or BevacizumaB

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517863-22-00

Acronym

LIBImAb

Enrollment

996

Registered

2024-11-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Study population consists in patients with a diagnosis of mCRC who have never received systemic treatment for advanced/metastatic disease and who are candidate to receive a first line therapy with FOLFIRI plus cetuximab or bevacizumab

Brief summary

The primary endpoint will be PFS

Detailed description

Overall survival, Objective Response Rate, Prevalence of RAS/BRAF mutation, Safety, Compliance

Interventions

DRUGIRINOTECAN

DRUGFLUOROURACIL

DRUGBEVACIZUMAB

DRUGCETUXIMAB

DRUGCALCIUM LEVOFOLINATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint will be PFS	—

Secondary

Measure	Time frame
Overall survival, Objective Response Rate, Prevalence of RAS/BRAF mutation, Safety, Compliance	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026